FY2025 Earnings Estimate for ResMed Issued By Zacks Research

ResMed Inc. (NYSE:RMD) – Research analysts at Zacks Research raised their FY2025 EPS estimates for ResMed in a report released on Thursday, March 13th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings per share of $9.37 for the year, up from their previous forecast of $9.36. The consensus estimate for ResMed’s current full-year earnings is $9.47 per share. Zacks Research also issued estimates for ResMed’s Q4 2025 earnings at $2.41 EPS, Q1 2026 earnings at $2.31 EPS, Q2 2026 earnings at $2.41 EPS, FY2026 earnings at $9.71 EPS and Q1 2027 earnings at $2.51 EPS.

RMD has been the topic of a number of other reports. UBS Group upgraded shares of ResMed from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 31st. Piper Sandler lifted their price objective on shares of ResMed from $252.00 to $260.00 and gave the company a “neutral” rating in a research report on Friday, January 31st. StockNews.com upgraded shares of ResMed from a “hold” rating to a “buy” rating in a research report on Saturday. Needham & Company LLC reiterated a “hold” rating on shares of ResMed in a research report on Friday, January 31st. Finally, Citigroup upgraded shares of ResMed from a “neutral” rating to a “buy” rating in a research report on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, ResMed currently has an average rating of “Moderate Buy” and a consensus price target of $243.82.

ResMed Stock Performance

Shares of RMD opened at $224.46 on Monday. The company has a current ratio of 3.33, a quick ratio of 2.29 and a debt-to-equity ratio of 0.13. The firm has a market cap of $32.97 billion, a PE ratio of 26.50, a price-to-earnings-growth ratio of 1.53 and a beta of 0.74. The company’s 50 day simple moving average is $236.09 and its 200-day simple moving average is $239.66. ResMed has a 12-month low of $172.19 and a 12-month high of $263.05.

ResMed (NYSE:RMD) last released its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share for the quarter, topping analysts’ consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%.

ResMed Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th will be issued a $0.53 dividend. The ex-dividend date is Thursday, February 13th. This represents a $2.12 dividend on an annualized basis and a yield of 0.94%. ResMed’s dividend payout ratio (DPR) is 25.03%.

Insider Buying and Selling at ResMed

In other news, Director Peter C. Farrell sold 2,000 shares of the company’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $242.11, for a total transaction of $484,220.00. Following the completion of the transaction, the director now owns 77,218 shares of the company’s stock, valued at $18,695,249.98. This represents a 2.52 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Kaushik Ghoshal sold 9,745 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $239.31, for a total transaction of $2,332,075.95. Following the transaction, the insider now directly owns 9,725 shares of the company’s stock, valued at approximately $2,327,289.75. This represents a 50.05 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 38,940 shares of company stock worth $9,164,385. Corporate insiders own 0.71% of the company’s stock.

Institutional Trading of ResMed

Institutional investors and hedge funds have recently bought and sold shares of the business. True Wealth Design LLC grew its position in ResMed by 2,200.0% in the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 110 shares in the last quarter. Colonial Trust Co SC grew its position in ResMed by 6,250.0% in the fourth quarter. Colonial Trust Co SC now owns 127 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 125 shares in the last quarter. Optiver Holding B.V. acquired a new stake in ResMed in the fourth quarter valued at approximately $33,000. Itau Unibanco Holding S.A. grew its position in ResMed by 1,000.0% in the fourth quarter. Itau Unibanco Holding S.A. now owns 165 shares of the medical equipment provider’s stock valued at $38,000 after acquiring an additional 150 shares in the last quarter. Finally, OFI Invest Asset Management acquired a new stake in ResMed in the fourth quarter valued at approximately $39,000. Institutional investors and hedge funds own 54.98% of the company’s stock.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.